Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Frexalimab
DRUG: Frexalimab
DRUG: MRI contrast-enhancing preparations

Sponsor

Sanofi